AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00972101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 by vein over 30 minutes as a single dose on Day -8
Study NCT00972101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 10 mg/kg by vein over 4 hours as a single dose on Day -7
Study NCT00972101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
Study NCT00972101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Regimen 1:~375 mg/m\^2 may be given by vein over 4 - 6 hours on Day -9 if needed~Regimen 2:~375 mg/m\^2 may be given by vein over 4 - 6 hours on Day -8 if needed
Study NCT00972101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60 mg/m\^2 by vein over 1-2 hours as a single dose on Day -3.
Study NCT00972101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Description: Regimen 1:~1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.~Regimen 2:~0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1.
Study NCT00972101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: 15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
Study NCT00972101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
Study NCT00972101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Infusion
Description: Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
Study NCT00972101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is > 2.5 x 10e\^9/L.
Study NCT00972101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex vivo expanded T cell Infusion
Description: Infusion by vein of treated cord blood beginning dose of 1 x 10e\^5 T cells/kg on Day 14+.
Study NCT04057066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: Physical activity counseling consists of two phone or video calls with a therapists, two group video calls with a therapist and a complementary e-learning course.
Study NCT04057066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for pwMS. However, they can be adjusted according to participants prior physical activity level and their available time slots for exercise during the week.
Study NCT04513756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach
Description: Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques. The first three sessions of the intervention are based upon rapport building, induction of the rationale of CRA and Functional analysis of usage and non-usage behavior.
Study NCT03973359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hygienic recommendations
Description: Recommendation of protective behaviours such as frequent hand washing and avoiding risky behaviours such as kissing young children on the mouth or cheeks and sharing utensils, foods etc.
Study NCT03450863 — intervention group
Intervention type: DRUG
Intervention: Fast-acting insulin aspart
Description: Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection \[MDI\]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion \[CSII\]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
Study NCT01050634 — intervention group
Intervention type: DRUG
Intervention: Aromasin (exemestane)
Description: 25mg oral tablet, daily, for >1yr
Study NCT00900510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision and drainage
Study NCT00900510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim/Sulfamethoxazole (Bactrim)
Description: Trimethoprim/Sulfamethoxazole, oral
Study NCT00900510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02587520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1
Description: 0.5 milliliter (mL), Intramuscular
Study NCT04258501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulberry fruit
Study NCT04258501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulberry leaf
Study NCT04258501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bean
Study NCT04258501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple
Study NCT04258501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elderberry
Study NCT02587520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2
Description: 0.5 mL, Intramuscular
Study NCT02587520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3
Description: 0.5 mL, Intramuscular
Study NCT02587520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4
Description: 0.5 mL, Intramuscular
Study NCT02587520 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed
Description: 0.5 mL, Intramuscular
Study NCT04258501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Turmeric
Study NCT02587520 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
Description: 0.5 mL, Intramuscular
Study NCT02730728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20ml bolus of 0.5% ropivicaine
Description: Local anesthetic
Study NCT02730728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Ropivicaine at 8 milliliter/hour
Description: Local anesthetic
Study NCT02730728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5ml bolus of 0.5% ropivicaine
Description: Local anesthetic
Study NCT01865266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinaststin for injection
Study NCT04258501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice porridge
Study NCT02863497 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based Sex Therapy
Description: These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
Study NCT01865266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02875535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLAS
Description: The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide).
Study NCT03623243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siponimod
Description: Siponimod 2mg tablets taken once daily
Study NCT02572544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)
Description: Wearing multiple and single pinhole glasses
Study NCT01378988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: For sedation according to protocol
Study NCT01545726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 was supplied as capsules for oral administration.
Study NCT01545726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as capsules for oral administration.
Study NCT02230735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bipivacaine 0.5% with epinephrine
Description: Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
Study NCT02230735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: (placebo for bupivacaine)
Study NCT03635463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: twin block appliance
Description: a functional appliance that enhances mandibular growth in growing patients made from vaccum sheets (esthetic)
Study NCT03635463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified twin block appliance
Description: a convetional twin block functional appliance that enhances mandibular growth in growing patients
Study NCT03959163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quick MRI
Description: A quick MRI scan takes about 15 mins or less. No IV or sedation will be necessary. The participant will be required to lie flat and still during the test. A parent will be allowed to be with the participant while they are in the scanner. The machine will produce loud intermittent sounds of banging or knocking so they will have to wear protective headphones. They can listen to music if they would like. If they are less than 1 year old, they will be swaddled and can be held during the test. If a child needs to have a parent in the scanner, it is ideal if the parent can have their head near the participant's legs and arms stretched out to hold the child's hands. If the parent needs to be by the patient's head, it can be accomplished by the parent lying head to head with the child or the parent lying on the child. Ideally they are lying head to head, or just outside of the scanner reaching in.
Study NCT02790996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.
Study NCT02790996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.
Study NCT04059510 — intervention group
Intervention type: PROCEDURE
Intervention: rectovaginal swab
Description: Self taken rectal and vaginal swab
Study NCT04059510 — intervention group
Intervention type: PROCEDURE
Intervention: pregnancy test
Description: Urine pregnancy test
Study NCT04059510 — intervention group
Intervention type: PROCEDURE
Intervention: Menstrual cup
Description: Menstrual cup vaginal fluid collection
Study NCT04059510 — intervention group
Intervention type: PROCEDURE
Intervention: Blood test
Description: Venous blood sample
Study NCT04059510 — intervention group
Intervention type: OTHER
Intervention: Focus group
Description: Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
Study NCT00746070 — intervention group
Intervention type: OTHER
Intervention: with the clinical treatment ( ex adrenalectomy or spironolactone
Description: with the clinical observational study
Study NCT02306746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TARGET protocol EN 1.5 kcal/mL
Description: Enteral feed 1.5 kcal/mL
Study NCT02306746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TARGET protocol EN 1.0 kcal/mL
Description: Enteral feed 1.0 kcal/mL
Study NCT03531385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Central sensitisation
Description: Central Sensitization Inventory, which is a comprehensive self-report inventory to assess the overlapping symptom dimensions of central sensitisation syndrome will be used to identify participants with central sensitisation.
Study NCT03531385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropathic pain
Description: Frequency of neuropatic pain will be investigated using Pain Detect Questionnaire
Study NCT03531385 — intervention group
Intervention type: OTHER
Intervention: Sleep disturbance
Description: Assessment of sleep disturbance will be assessed by Pittsburgh Sleep Quality Index
Study NCT03531385 — intervention group
Intervention type: OTHER
Intervention: Quality of life
Description: Quality of life will be assessed by the Nottingham Health Profile
Study NCT02093884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Study NCT02093884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Referral
Study NCT01347801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
Study NCT01347801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Normal saline (NaCl 0,9%)
Study NCT01347801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF-alfa
Description: 1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
Study NCT01347801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNF-alfa
Description: 1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
Study NCT00859547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rThrombin, 1000 IU/mL
Description: rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
Study NCT01302483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% tetracaine HCL with 0.05% oxymetazoline HCL
Description: 1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.
Study NCT01302483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Injection
Description: Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.
Study NCT01638663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: 15 mg pr day for 1 day
Study NCT01638663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet Unikalk 1 pr day for 1 day
Study NCT02863614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Study NCT02863614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Study NCT02863614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Study NCT02863614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01347801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g glucose
Study NCT01347801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g glucose
Study NCT01347801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g glucose
Study NCT02863614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01173601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Study NCT01173601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01173601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
Study NCT01173601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
Study NCT01347801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVGTT
Description: Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
Study NCT01347801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IVGTT
Description: Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
Study NCT01106599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0623
Description: Repeating oral dose
Study NCT01347801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVGTT
Description: Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
Study NCT02629029 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pre-op CTA with IV contrast
Description: Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H\&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.
Study NCT02629029 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Computed tomography angiography (CTA)
Study NCT01033539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic strain ATCC PTA 4659
Description: Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1\*10 10 CFU/bag Low dose of ATCC PTA 4659 1\*10 8 CFU/bag
Study NCT03876717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam Hydrochloride
Description: Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
Study NCT03876717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Inactive placebo tablets over-encapsulated with DB caps AAA
Study NCT03089021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan mobilization
Description: mobilization with movement for spinous process or facet joint.
Study NCT03089021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maitland mobilization
Description: posterioanterior of spinous process or facet joint.
Study NCT02754570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: Pilocarpine will be administered 4 times in addition to latanoprost.
Study NCT04608721 — intervention group
Intervention type: OTHER
Intervention: Postpartum Anxiety
Description: Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI) with a score ≥40 serving as a positive screen.
Study NCT01121146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Replacement
Description: Comparison of Marathon and Enduron polyethylene
Study NCT00733785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: Rosiglitazone extended release formulation
Study NCT01467011 — intervention group
Intervention type: DRUG
Intervention: Enteric-coated Mycophenolate Sodium
Description: 1440mg/day for 6 months posttransplant
Study NCT04118465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external cephalic version
Description: external cephalic version
Study NCT01290315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)